Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GQ1001 and Pyrotinib in HER2 Positive Metastatic Breast Cancer
NCT05575804Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Oct 2022
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of GQ1001 in breast cancer, sponsored by Fudan University. Started Oct 2022; status: recruiting.
02
Drugs
GQ1001
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05575804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05575804.